1. Home
  2. XAIR vs CDIO Comparison

XAIR vs CDIO Comparison

Compare XAIR & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.43

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

N/A

Current Price

$1.96

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XAIR
CDIO
Founded
2011
2017
Country
United States
United States
Employees
N/A
17
Industry
Medical/Dental Instruments
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.7M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
XAIR
CDIO
Price
$0.43
$1.96
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
259.8K
36.6K
Earning Date
06-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,679,000.00
N/A
Revenue This Year
$122.00
$171,906.75
Revenue Next Year
$58.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
107.26
N/A
52 Week Low
$0.33
$0.97
52 Week High
$3.78
$7.91

Technical Indicators

Market Signals
Indicator
XAIR
CDIO
Relative Strength Index (RSI) 47.89 48.47
Support Level $0.36 $1.68
Resistance Level $0.52 $2.13
Average True Range (ATR) 0.05 0.16
MACD 0.01 -0.02
Stochastic Oscillator 52.70 20.10

Price Performance

Historical Comparison
XAIR
CDIO

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Share on Social Networks: